The trusted source for
healthcare information and
Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology worldwide and is the third leading cause of liver transplantation in the United States.This article reviews the pathogenesis, diagnosis, and natural history of NAFLD as well as known treatments and future therapies.
Financial Disclosure: To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, Dr. Wise (editor) reports he is involved with sales for CNS Vital Signs, Clenn Sweep, and AdmeraHealth. Dr. Shubrook reports he is a consultant for Eli Lilly, NovoNordisk, and Intarcia. Dr. Pfotenhauer (author), Dr. Young (author), Ms. Dugan (author), Dr. Abraham (peer reviewer), Ms. Coplin (executive editor), Ms. Mark (executive editor), and Ms. Hatcher (editorial group manager) report no financial relationships with companies related to the field of study covered by this CME activity.